Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Hyperlipoproteinemias

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 231 articles:
HTML format
Text format



Single Articles


    February 2018
  1. ZHAO Y, Yang Y, Xing R, Cui X, et al
    Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats.
    Atherosclerosis. 2018;271:26-35.
    PubMed     Text format     Abstract available


  2. VITVEROVA B, Blazickova K, Najmanova I, Vicen M, et al
    Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Atherosclerosis. 2018;271:15-25.
    PubMed     Text format     Abstract available


    January 2018
  3. PELCZARSKA A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, et al
    The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Atherosclerosis. 2018;270:132-138.
    PubMed     Text format     Abstract available


  4. RODRIGUEZ-BORJABAD C, Ibarretxe D, Girona J, Ferre R, et al
    Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Atherosclerosis. 2018;270:117-122.
    PubMed     Text format     Abstract available


  5. KAYIKCIOGLU M, Tokgozoglu L, Yilmaz M, Kaynar L, et al
    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Atherosclerosis. 2018;270:42-48.
    PubMed     Text format     Abstract available


  6. DROUIN-CHARTIER JP, Tremblay AJ, Bergeron J, Lamarche B, et al
    High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Atherosclerosis. 2018;270:26-32.
    PubMed     Text format     Abstract available


    December 2017
  7. PEK SLT, Dissanayake S, Fong JCW, Lin MX, et al
    Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Atherosclerosis. 2017;269:106-116.
    PubMed     Text format     Abstract available


  8. SANCHEZ-HERNANDEZ RM, Prieto-Matos P, Civeira F, Lafuente EE, et al
    Autosomal recessive hypercholesterolemia in Spain.
    Atherosclerosis. 2017;269:1-5.
    PubMed     Text format     Abstract available


    October 2017
  9. HOEKE G, Wang Y, van Dam AD, Mol IM, et al
    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2017;267:116-126.
    PubMed     Text format     Abstract available


  10. AMROCK SM, Duell PB, Knickelbine T, Martin SS, et al
    Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry.
    Atherosclerosis. 2017;267:19-26.
    PubMed     Text format     Abstract available


    September 2017
  11. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Text format     Abstract available


  12. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Text format     Abstract available


  13. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Text format     Abstract available


    August 2017
  14. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Text format     Abstract available


  15. SPINA R, Cefalu' AB, Noto D, Ingrassia V, et al
    Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  16. ELLIS K, Pang J, Bell D, Burnett J, et al
    Elevated lipoprotein(a) and familial hypercholesterolaemia phenotypes in patients admitted to a coronary care unit with coronary artery disease.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  17. MINICOCCI I, Pozzessere S, Prisco C, Montali A, et al
    Mutational analysis of children and adolescents with familial hypercholesterolemia ascertained by child-parent screening.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  18. COUVERT P, Giral P, Boelle PY, Carreau V, et al
    Genetic testing of familial hypercholesterolemia: Monogenic form and polygenic contribution to cardiovascular risk.
    Atherosclerosis. 2017;263:e94.
    PubMed     Text format    


  19. GAUDET D, Gipe D, Hovingh K, Ahmad Z, et al
    Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, proof-of-concept study.
    Atherosclerosis. 2017;263:e9.
    PubMed     Text format    


  20. GHALEB Y, Elbitar S, El Khoury P, Rabes JP, et al
    Usefulness of the genetic risk score to identify phenocopies in families with autosomal dominant hypercholesterolemia?
    Atherosclerosis. 2017;263:e83.
    PubMed     Text format    


  21. VERBEEK R, Oldoni F, Boekholdt SM, Zwinderman A, et al
    Multilocus gene score or a metabolic risk score for severe hypertriglyceridemia and CVD risk prediction.
    Atherosclerosis. 2017;263:e83.
    PubMed     Text format    


  22. MUNDAL L, Igland J, Tell GS, Veierod M, et al
    Standardized incidence ratio of peripheral arterial disease and aortic stenosis in genotyped familial hypercholesterolemia in Norway during 2001-2009.
    Atherosclerosis. 2017;263:e78.
    PubMed     Text format    


  23. HUSEYNOV R, Kayikcioglu M, Bayraktaroglu S, Can L, et al
    The relationship between lipoprotein A and aortic calsification in patients with hypercholesterolemia.
    Atherosclerosis. 2017;263:e67.
    PubMed     Text format    


  24. BENEDEK P, Angelin B, Duvefelt K, Hong J, et al
    The use of genotyping as a first step in molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e62.
    PubMed     Text format    


  25. PANG J, Abraham A, Bates TR, Bell DA, et al
    Subclinical coronary artery disease in asymptomatic patients with and without genetically confirmed familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e61-e62.
    PubMed     Text format    


  26. MEDEIROS AM, Alves AC, Bourbon M
    APOB/APOA1 ratio and APOC2 are the best biomarkers to distinguish familial hypercholesterolemia from other dyslipidaemia.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  27. RYAN JD, Pang J, Watts GF, Vickery A, et al
    Using general practice electronic databases to increase the identification of familial hypercholesterolaemia in primary care.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  28. RAMO J, Ripatti P, Tabassum R, Soderlund S, et al
    Mass spectrometry of circulating lipid species highlights similarity of familial hyperlipidemias and hyperlipidemias in the general population.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  29. RAHMAT R, Chua YA, Ismail Z, Mohd Kasim NA, et al
    Elevated serum lipoprotein(A) concentrations in different sub-groups of clinical familial hypercholesterolaemia and their unaffected family members.
    Atherosclerosis. 2017;263:e60.
    PubMed     Text format    


  30. CHRISTENSEN JJ, Osnes L, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e58.
    PubMed     Text format    


  31. OLIYARNYK O, Markova I, Malinska H, Trnovska J, et al
    Combination of silymarin with N-3 Polyunsaturated fatty acids enhances hepatoprotective effect of silymarin in hereditary hypertriglyceridemic rats.
    Atherosclerosis. 2017;263:e44.
    PubMed     Text format    


  32. HANDE L, Thunhaug H, Enebakk T, Ludviksen JA, et al
    Addition of polyunsaturated fatty acids to statins in familial hypercholesterolemia does not affect in vitro or in vivo endothelial function.
    Atherosclerosis. 2017;263:e43.
    PubMed     Text format    


  33. GONZALEZ-ESTRADA A, Alarcon-Garcia JC, Garcia-Ocana P, Camacho-Carrasco A, et al
    Alirocumab in patients with heterozygous familial hypercholesterolemia: Clinical experience in 27 patients at a tertiary care center in Southern Spain.
    Atherosclerosis. 2017;263:e42-e43.
    PubMed     Text format    


  34. DOWNIE P, Gritzmacher L, Palmer F, Bayly G, et al
    The variable effect of PCSK9 inhibition in patients with homozygous familial hypercholesterolaemia: Evidence to support the existence of alternative cholesterol lowering pathways.
    Atherosclerosis. 2017;263:e42.
    PubMed     Text format    


  35. PEREZ-CALAHORRA S, Plana N, Ma Sanchez-Hernandez R, Marco-Benedi V, et al
    Candidates for monoclonal antibodies to PCSK9, among heterozygous familial hypercholesterolemia patients in the dyslipidemia registry of the Spanish atherosclerosis society.
    Atherosclerosis. 2017;263:e41-e42.
    PubMed     Text format    


  36. RIPATTI P, Ramo J, Soderlund S, Surakka I, et al
    Polygenic hyperlipidemia and coronary artery disease risk.
    Atherosclerosis. 2017;263:e4.
    PubMed     Text format    


  37. LAMIQUIZ MONEO I, Baila Rueda L, Bea Sanz AM, Gallego RM, et al
    ABCG5/G8 mutations in non FH genetic hypercholesterolemias.
    Atherosclerosis. 2017;263:e39-e40.
    PubMed     Text format    


  38. BIGOLIN P, Antonucci A, Marin R, Vianello D, et al
    Genetic diagnosis of familial hypercholesterolaemia: Preliminary data from the university of padua outpatient lipid clinic.
    Atherosclerosis. 2017;263:e39.
    PubMed     Text format    


  39. HUMPHRIES S, Futema M, Cooper J, Charakida M, et al
    SEnsitivity and specificity of biochemical screening for familial hypercholesterolaemia in childhood: avon longitudinal study of parents and children (ALSPAC).
    Atherosclerosis. 2017;263:e39.
    PubMed     Text format    


  40. PETROV I, Postadzhiyan A, Tokmakova M, Addison J, et al
    Management of high and very high risk patients with familial hypercholesterolemia: Results from an observational study in Bulgaria.
    Atherosclerosis. 2017;263:e38-e39.
    PubMed     Text format    


  41. BAILA-RUEDA L, Civeira F, Lamiquiz-Moneo I, Mateo-Gallego R, et al
    Familial combined hypercholesterolemia differs from other genetic hypercholesterolemias in the hepatic cholesterol production.
    Atherosclerosis. 2017;263:e38.
    PubMed     Text format    


  42. GARCIA UG, Vicente AB, Etxebarria A, Palacios L, et al
    The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants.
    Atherosclerosis. 2017;263:e37.
    PubMed     Text format    


  43. NOHARA A, Kawashiri MA, Eto Y, Fujisaki M, et al
    Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e37-e38.
    PubMed     Text format    


  44. SIMIONESCU N, Carnuta MG, Fuior EV, Stancu CS, et al
    Targeting lipid metabolism-related genes by in vivo inhibition of MIR-486 and MIR-92A lowers plasma cholesterol levels in hyperlipidemic hamsters.
    Atherosclerosis. 2017;263:e34-e35.
    PubMed     Text format    


  45. BARALE C, Bonomo K, Noto F, Traversa M, et al
    Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia.
    Atherosclerosis. 2017;263:e30-e31.
    PubMed     Text format    


  46. BASSANI BORGES J, Medeiros Bastos G, Almendros Afonso TK, Da Silva Rodrigues E, et al
    Next generation sequencing in the diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e282.
    PubMed     Text format    


  47. SHCHERBAKOVA N, Ershova A, Zharikova A, Meshkov A, et al
    Genetics of familial hypercholesterolemia in patients recruited from epidemiological study.
    Atherosclerosis. 2017;263:e281.
    PubMed     Text format    


  48. RONEN D, Ibe UK, Shoshi S, Daniel S, et al
    Molecular genetics of familial hypercholesterolemia in Israel - revisited.
    Atherosclerosis. 2017;263:e279-e280.
    PubMed     Text format    


  49. DLOUHA D, Blaha M, Blaha V, Fatorova I, et al
    Analysis of circulating mirnas in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Atherosclerosis. 2017;263:e278.
    PubMed     Text format    


  50. ZHILINA S, Miramontes Gonzalez JP, Laso Guzman FJ
    Familial hypercholesterolemia and the diabetogenic effect of statins.
    Atherosclerosis. 2017;263:e264.
    PubMed     Text format    


  51. LIND L, Onnerhag K, Riserus U, Kvarnstrom M, et al
    Effects of free omega-3 carboxylic acids and fenofibrate on liver steatosis and serum lipoproteins in overweight patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).
    Atherosclerosis. 2017;263:e260.
    PubMed     Text format    


  52. RETTERSTOL K, Mundal L, Igland J, Seppola Tell G, et al
    Incidence of various types of atherosclerotic disease in patients with genotyped familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e26.
    PubMed     Text format    


  53. TICHY L, Pavlouskova J, Reblova K, Freiberger T, et al
    Autosomal dominant hypercholesterolemia in the czech republic - introduction of the next generation sequencing.
    Atherosclerosis. 2017;263:e26.
    PubMed     Text format    


  54. PAPAKONSTANTINOU P, Theodoraki E, Koulentaki M, Papadakis J, et al
    New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids?
    Atherosclerosis. 2017;263:e253-e254.
    PubMed     Text format    


  55. GROSELJ U, Kovac J, Klancar G, Pohleven S, et al
    Characteristics of children with familial and polygenic hypercholesterolemia referred through the national universal hypercholesterolemia screening - a preliminary report.
    Atherosclerosis. 2017;263:e25-e26.
    PubMed     Text format    


  56. SIMONELLI F, Miotti C, Filice BF, Gallo G, et al
    Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH).
    Atherosclerosis. 2017;263:e246-e247.
    PubMed     Text format    


  57. GRAESDAL A, Dybvig A
    Lipoprotein apheresis as a treatment modality for familial combined hyperlipidemia (FCH) with non-alcoholic fatty liver disease (NAFLD) and coronary heart disease: a casuistic approach.
    Atherosclerosis. 2017;263:e243-e244.
    PubMed     Text format    


  58. VALLEJO-VAZ AJ, Roth EM, Hovingh GK, Lee LV, et al
    Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e243.
    PubMed     Text format    


  59. UZOKOV J, Alyavi A, Alyavi B
    Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome.
    Atherosclerosis. 2017;263:e241.
    PubMed     Text format    


  60. YASUDA H, Fujiwara A, Komiya S, Haze T, et al
    Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate.
    Atherosclerosis. 2017;263:e241-e242.
    PubMed     Text format    


  61. HUMPHRIES S, Pears R, Miedzybrodzka Z, Haralambos K, et al
    Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from FH services in the UK.
    Atherosclerosis. 2017;263:e24-e25.
    PubMed     Text format    


  62. GONZALEZ MOLERO I, Olveira G, Tinahones F
    Features of first patients treated with PCSK9 inhibitors in a specific lipid unit and effectiveness on lipid profile in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e239.
    PubMed     Text format    


  63. GURINA N, Loukianov M, Martsevich S, Zagrebelny A, et al
    Prescription patterns of lipid-lowering therapy in patients with cardiovascular disease and hypertriglyceridemia in real clinical practice in Russia.
    Atherosclerosis. 2017;263:e237.
    PubMed     Text format    


  64. IACOCCA M, Wang J, Dron J, Robinson J, et al
    Use of next-generation sequencing to detect copy number variations in the molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e236.
    PubMed     Text format    


  65. WU X, Pang J, Peng J, Chen Y, et al
    Effectiveness of reverse cascade screening for familial hypercholesteroleamia in very high risk families in China.
    Atherosclerosis. 2017;263:e235-e236.
    PubMed     Text format    


  66. GIAMMANCO A, Spina R, Ingrassia V, Valenti V, et al
    Genotypic and phenotypic characterization of patients with autosomal dominant hypercholesterolemia in sicily.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  67. BEHESHTI S, Madsen CM, Varbo A, Nordestgaard BG, et al
    2.6-fold risk of ischemic stroke in individuals with clinical familial hypercholesterolemia: The copenhagen general population study with 102,961 individuals.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  68. CASULA M, Chiodo L, Garlaschelli K, Galimberti F, et al
    Characterization of Italian patients with familial hypercholesterolemia: The lipigen study.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  69. SCHWARZOVA L, Horinek A, Hubacek J, Zlatohlavek L, et al
    Mutation analysis of the LDLR gene in Czech hypercholesterolemic patients.
    Atherosclerosis. 2017;263:e234.
    PubMed     Text format    


  70. KAYA E, Kayikcioglu M, Payzin S, Can LH, et al
    Aortic elastic properties of familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e234-e235.
    PubMed     Text format    


  71. LATKOVSKIS G, Saripo V, Gilis D, Upena-Roze A, et al
    The first results of the Latvian registry of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e233.
    PubMed     Text format    


  72. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2017;263:e233.
    PubMed     Text format    


  73. SCHMIDT N, Dressel A, Marz W
    First data from the German cascade screening program for familial hypercholesterolemia - care high.
    Atherosclerosis. 2017;263:e233-e234.
    PubMed     Text format    


  74. COCCI G, Cenci A, Bordicchia M, Sarzani R, et al
    LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family.
    Atherosclerosis. 2017;263:e232.
    PubMed     Text format    


  75. ARNESEN KE, Mork I, Thorwall M, Retterstol K, et al
    Treat-to-target familial hypercholesterolemia (TTT-FH)-a prospective study of high-intensity lipid treatment in free living patients with familial hypercholesterolemia (FH).
    Atherosclerosis. 2017;263:e232-e233.
    PubMed     Text format    


  76. COHEN H, Pinhas-Hamie O, Harats D, Bitzur R, et al
    Carotid imt and plasma lipid levels among children and adolescents with familial hypercholesterolemia. A single center experience 2007-2014.
    Atherosclerosis. 2017;263:e232.
    PubMed     Text format    


  77. SEMENOVA A, Sergienko I, Ezhov M, Garcia-Giustiniani D, et al
    The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing.
    Atherosclerosis. 2017;263:e231.
    PubMed     Text format    


  78. LIN J, Wu X
    Cascade screening, clinical features and genetic aspects-familial hypercholesterolemia study in China.
    Atherosclerosis. 2017;263:e231.
    PubMed     Text format    


  79. SOLOVIEVA E, Ezhov M, Shakhnovich R, Titov V, et al
    Frequency of familial hypercholesterolemia in patients with premature acute coronary syndrome.
    Atherosclerosis. 2017;263:e230-e231.
    PubMed     Text format    


  80. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  81. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  82. ALARCON GARCIA JC, Gonzalez Estrada A, Camacho Carrasco A, Garcia Ocana P, et al
    Combination therapy of Evolocumab and LDL apheresis in patients with heterozygous familial hypercholesterolemia: A case series.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  83. REKALDE LS, Kovtsun J, Gorzelak-Pabis P, Zuszek-Frynas A, et al
    The incidence of familiar hypercholesterolemia in patients of the cardiology and internal diseases department in a Lodz hospital and their treatment analysis.
    Atherosclerosis. 2017;263:e228-e229.
    PubMed     Text format    


  84. ALVES AC, Medeiros AM, Padeira G, Ferreira AC, et al
    Sitosterolaemia: A case of rare hypercholesterolaemia in Fh patient's cohort.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  85. PANG J, Abraham A, Bates TR, Bell DA, et al
    Predictors of subclinical coronary artery disease in asymptomatic patients with familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  86. POJSKIC B, Stimjanin E, Pojskic L, Selimovic H, et al
    Connection between foreign body in the eye and familial hypercholesterolemia -case report.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  87. SHAKHTSHNEIDER E, Orlov P, Ivanoshchuk D, Makarenkova K, et al
    Analysis of the LDLR gene variability in patients with familial hypercholesterolemia in Russia using targeted high throughput resequencing.
    Atherosclerosis. 2017;263:e227.
    PubMed     Text format    


  88. BATURINA O, Mironova O
    Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke.
    Atherosclerosis. 2017;263:e227-e228.
    PubMed     Text format    


  89. GRITZMACHER L, Bayly G, Honeychurch J, Williams M, et al
    The critical role of segregation analysis in determining the pathogenicity of variants of uncertain significance in patients with suspected familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  90. HUBACEK JA, Adamkova V, Lanska V, Dlouha D, et al
    Polygenous hypercholesterolemia. Replication of GWAS results on Czech slavonic population.
    Atherosclerosis. 2017;263:e226-e227.
    PubMed     Text format    


  91. HUBACEK JA, Adamkova V, Vrablik M, Ceska R, et al
    Common polymorphisms as strong predictors of hypertriglyceridemia in Czech population.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  92. URAZGILDEEVA S, Muzalevskaya M, Tregubov A, Nekrasova T, et al
    Main cardiovascular risk factors and HDL rather than LDL and LP(a) levels predict premature atherosclerotic cardiovascular disease in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  93. MOLLAKI V, Drogari E
    Molecular findings of monogenic familial hypercholesterolemia in the Greek population.
    Atherosclerosis. 2017;263:e225.
    PubMed     Text format    


  94. KYSELAK O, Freiberger T, Kovar J, Tichy L, et al
    Atypical phenotype of homozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  95. ILIC GG
    LDL cholesterol and familial hypercholesterolemia in children. Significance of familial history in detecting familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  96. KHOKHLOV R, Tribuntseva L, Burlachuk V, Khokhlov L, et al
    Search strategy of familial hypercholesterolemia among hospitalized patients.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  97. CHORA JR, Alves AC, Medeiros AM, Bourbon M, et al
    Systematic review of LDLR mutations associated to familial hypercholesterolaemia - evidence of functional studies and application of acmg guidelines for FH diagnosis.
    Atherosclerosis. 2017;263:e221.
    PubMed     Text format    


  98. OGURA M, Morimoto M, Harada-Shiba M
    Antioxidant property of HDL as well as cholesterol efflux capacity are independent risk markers for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e218.
    PubMed     Text format    


  99. DACLAT R, Bittar R, Salem JE, Ricaldi S, et al
    Postprandial apolipoprotein B-48 level is independent of insulin secretion in patients with moderate or severe hypertriglyceridemia.
    Atherosclerosis. 2017;263:e211.
    PubMed     Text format    


  100. OYRI LKL, Hansson P, Bogsrud MP, Narverud I, et al
    Postprandial response after intake of saturated fat compared to polyunsaturated fat in subjects with familial hypercholesterolemia and normolipidemic controls-a randomized controlled trial.
    Atherosclerosis. 2017;263:e210.
    PubMed     Text format    


  101. GRIVA E, Kyrkou K, Stamatelopoulos K, Drogari E, et al
    The effect of Lp(a) on cardiovascular function in greek pediatric population 6-16 years old. Preliminary findings in children with or without familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e207-e208.
    PubMed     Text format    


  102. SEED M, Sharifi M, Nair D, Jain A, et al
    Lipoprotein(a) level is higher inpatients with familial hypercholesterolaemia than in normal healthy subjects, contribution of variants in the LPA gene.
    Atherosclerosis. 2017;263:e207.
    PubMed     Text format    


  103. POLYPATHELLI I, Demosthenous C, Gavra M, Matsaridou E, et al
    Hypertriglyceridemia-induced acute pancreatitis in third trimester of pregnancy: A case report.
    Atherosclerosis. 2017;263:e203-e204.
    PubMed     Text format    


  104. BENIMETSKAYA K, Ragino Y, Shakhtshneider E, Makarenkova K, et al
    Proprotein convertase subtilisin/kexin type 9 (PCSK9) level in patients with familial hypercholesterolemia in Russia.
    Atherosclerosis. 2017;263:e195.
    PubMed     Text format    


  105. ERSHOVA A, Meshkov A, Bazhan S, Storozhok M, et al
    The prevalence of heterozygous familial hypercholesterolemia in the Russian Federation: A substudy of the ESSE-Rf.
    Atherosclerosis. 2017;263:e184-e185.
    PubMed     Text format    


  106. FARES AL, Hussein El Bacha AA, Souza CS, Garcia De Carvalho JA, et al
    High prevalence of familial hypercholesterolemia in patients with coronary heart disease at a Brazilian quaternary healthcare center.
    Atherosclerosis. 2017;263:e181-e183.
    PubMed     Text format    


  107. SCICALI R, Platania R, Purrazzo G, Giannone A, et al
    Screening for unknown hypercholesterolemia in a hospital population: A model for preventive medicine.
    Atherosclerosis. 2017;263:e181.
    PubMed     Text format    


  108. ALVES R, Yamaya A, Souza A, Rosa R, et al
    Identification of patients with familial hypercholesterolemia in dyslipidemia ambulatory of public hospital.
    Atherosclerosis. 2017;263:e179.
    PubMed     Text format    


  109. IYENGAR S, Gupta R, Ravi S
    Looking for a needle in a haystack? Familial hypercholesterolemia in coronary artery disease.
    Atherosclerosis. 2017;263:e177.
    PubMed     Text format    


  110. DUMITRESCU A, Mosteoru S, Gaita D, Mut G, et al
    The prevalence of familial hypercholesterolemia in children from Timisoara.
    Atherosclerosis. 2017;263:e170-e171.
    PubMed     Text format    


  111. SANZ AMB, Jarauta E, Perez-Calahorra S, Marco-Benedi V, et al
    Association between carotid plaque and coronary events in subjects with genetic hypercholesterolemia.
    Atherosclerosis. 2017;263:e17-e18.
    PubMed     Text format    


  112. GOCMEN AY, Gumuslu S
    Atorvastatin influences oxidative stress markers in hypercholesterolemic rats.
    Atherosclerosis. 2017;263:e162.
    PubMed     Text format    


  113. ALYAHYA AM, Al Masri A, Eleter E, Alhersi A, et al
    Progranulin attenuates in vivo acute myocardial ischemia/reperfusion injury in a rat model of hypercholesterolemia.
    Atherosclerosis. 2017;263:e148-e149.
    PubMed     Text format    


  114. FUSTER JJ, Maclauchlan S, Zuriaga MA, Polackal MN, et al
    Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis in hyperlipidemic mice.
    Atherosclerosis. 2017;263:e14.
    PubMed     Text format    


  115. KRITIKOU E, Van Der Heijden T, Maarten S, Van Duijn J, et al
    Hypercholesterolemia induces a mast cell-CD4+ T-cell interaction in atherosclerosis.
    Atherosclerosis. 2017;263:e124.
    PubMed     Text format    


  116. MOREGOLA A, Bonacina F, Coe D, Pellegatta F, et al
    LDLR influence on CD4 T cells differentiation in mice and in familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e115.
    PubMed     Text format    


  117. MACCHI C, Botta M, Bosisio R, Pavanello C, et al
    Efficacy and safety of a nutraceutical with probiotic and red yeast rice extract in patients with moderate hypercholesterolemia: A randomized, double-blind, placebo-controlled study.
    Atherosclerosis. 2017;263:e109.
    PubMed     Text format    


  118. OGURA M, Furuhashi M, Morimoto M, Matsumoto M, et al
    Fatty acid-binding protein 5 as a residual risk for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e100.
    PubMed     Text format    


    July 2017
  119. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Text format     Abstract available


  120. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Text format     Abstract available


  121. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Text format     Abstract available


    June 2017
  122. SUDO M, Li Y, Hiro T, Takayama T, et al
    Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.
    Atherosclerosis. 2017 Jun 23. pii: S0021-9150(17)31169.
    PubMed     Text format     Abstract available


  123. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Text format     Abstract available


  124. BERBEE JFP, Mol IM, Milne GL, Pollock E, et al
    Deuterium-reinforced polyunsaturated fatty acids protect against atherosclerosis by lowering lipid peroxidation and hypercholesterolemia.
    Atherosclerosis. 2017 Jun 21. pii: S0021-9150(17)31165.
    PubMed     Text format     Abstract available


  125. SANTOS RD, Miname MH
    Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?
    Atherosclerosis. 2017 Jun 12. pii: S0021-9150(17)30254.
    PubMed     Text format    


  126. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Text format     Abstract available


  127. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Text format     Abstract available


    May 2017
  128. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Text format     Abstract available


  129. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Text format     Abstract available


  130. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Text format     Abstract available


  131. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Text format     Abstract available


    April 2017
  132. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Text format     Abstract available


  133. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Text format     Abstract available


    March 2017
  134. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Text format     Abstract available


  135. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Text format     Abstract available


    February 2017
  136. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available


  137. JANUS ED
    Homozygous familial hypercholesterolaemia - Early recognition and early treatment improve outcomes.
    Atherosclerosis. 2017 Feb 16. pii: S0021-9150(17)30060.
    PubMed     Text format    


  138. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available


  139. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Text format     Abstract available


    January 2017
  140. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Text format     Abstract available


  141. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Text format     Abstract available


  142. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Text format     Abstract available


    December 2016
  143. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Text format     Abstract available


  144. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Text format     Abstract available


  145. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Text format     Abstract available


  146. BOOT C, Holmes E, Neely RD
    Serum non-HDL cholesterol to apolipoprotein B ratio as a screening test for familial dysbetalipoproteinaemia (Type III hyperlipidaemia) in patients with mixed hyperlipidaemia.
    Atherosclerosis. 2016;255:7.
    PubMed     Text format    


  147. HARALAMBOS K, Ashfield-Watt P, Edwards R, Gingell R, et al
    Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?
    Atherosclerosis. 2016;255:7-8.
    PubMed     Text format    


  148. HONEYCHURCH J, Watson E, Hills A, Dean P, et al
    Validation and utility of a new NGS assay for familial hypercholesterolaemia incorporating 12 LDL-C-raising SNPs.
    Atherosclerosis. 2016;255:6-7.
    PubMed     Text format    


  149. GOYALE A, Jain A, Sharifi M, Gallivan A, et al
    Validation of low density lipoprotein correction factors in a multi-ethnic familial hypercholesterolaemia population at a North London lipid clinic.
    Atherosclerosis. 2016;255:6.
    PubMed     Text format    


  150. SHARIFI M, Jain A, Persaud J, Humphries SE, et al
    Cardiovascular biomarkers in monogenic familial hypercholesterolaemia and polygenic hypercholesterolaemia.
    Atherosclerosis. 2016;255:4.
    PubMed     Text format    


  151. HILLS A, Honeychurch J, Davies J, Robinson C, et al
    4 years' cascade genetic testing for familial hypercholesterolaemia in England - Increased referrals and ascertainment.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  152. KATE HARALAMBOS K, Whitmore J
    Using pass database and geographic information systems (GIS) to map familial hypercholesterolaemia (FH) diagnoses in England and Wales.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  153. LUNGLEY J, Jayne Z, Harvey D, Nair DR, et al
    Early identification of familial hypercholesterolaemIa (FH): The prevention of Cardiovascular disease (CVD).
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  154. GRITZMACHER L, Bayly GR, Williams M, Hills A, et al
    The critical importance of segregation analysis in the management of patients and their families with suspected familial hypercholesterolaemia: 3 examples from the bristol FH clinic.
    Atherosclerosis. 2016;255:2-3.
    PubMed     Text format    


  155. COZENS A, McMahon S, Purves J, Miedzybrodska Z, et al
    Detection, assessment and treatment of children with familial hypercholesterolaemia in Scotland.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  156. GELLATLY E
    Familial hypercholesterolaemia (FH) - Finding the needle in a haystack in a Scottish population.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  157. ASHFIELD-WATT P, Haralambos K, Edwards R, Townsend D, et al
    Estimation of the prevalence of cholesteryl ester storage disorder (CESD) in a cohort of patients with clinical features of familial hypercholesterolaemia.
    Atherosclerosis. 2016;255:1.
    PubMed     Text format    


    November 2016
  158. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Text format     Abstract available


    October 2016
  159. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Text format     Abstract available


  160. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Text format     Abstract available


  161. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Text format     Abstract available


  162. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Text format     Abstract available


    September 2016
  163. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.
    PubMed     Text format    


  164. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Text format     Abstract available


  165. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Text format     Abstract available


  166. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Text format     Abstract available


    August 2016
  167. ALONSO R, Mata P, Muniz O, Fuentes-Jimenez F, et al
    PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Atherosclerosis. 2016 Aug 27. pii: S0021-9150(16)31306.
    PubMed     Text format     Abstract available


  168. GRENKOWITZ T, Kassner U, Wuhle-Demuth M, Salewsky B, et al
    Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Atherosclerosis. 2016;253:88-93.
    PubMed     Text format     Abstract available


    July 2016
  169. WATTS GF, Pang J, Chan DC, Brunt JN, et al
    Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Atherosclerosis. 2016;252:82-87.
    PubMed     Text format     Abstract available


  170. ROETERS VAN LENNEP JE
    Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia.
    Atherosclerosis. 2016 Jul 30. pii: S0021-9150(16)31229.
    PubMed     Text format    


  171. TORVIK K, Narverud I, Ottestad I, Svilaas A, et al
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;252:21-27.
    PubMed     Text format     Abstract available


  172. SCHOFIELD J, Kwok S, France M, Capps N, et al
    Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Atherosclerosis. 2016 Jul 10. pii: S0021-9150(16)30308.
    PubMed     Text format     Abstract available


  173. SJOUKE B, Defesche JC, de Randamie JS, Wiegman A, et al
    Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2016;251:263-265.
    PubMed     Text format     Abstract available


    May 2016
  174. SILVA PR, Jannes CE, Marsiglia JD, Krieger JE, et al
    Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Atherosclerosis. 2016;250:144-150.
    PubMed     Text format     Abstract available


  175. GUARDIOLA M, Cofan M, de Castro-Oros I, Cenarro A, et al
    Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104].
    Atherosclerosis. 2016 May 12. pii: S0021-9150(16)30169.
    PubMed     Text format    


  176. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Text format     Abstract available


  177. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


    April 2016
  178. KRAUZOVA E, Kracmerova J, Rossmeislova L, Malisova L, et al
    Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women.
    Atherosclerosis. 2016;250:151-157.
    PubMed     Text format     Abstract available


    March 2016
  179. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Text format     Abstract available


  180. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Text format     Abstract available


  181. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Text format     Abstract available


  182. SANTOS RD
    Homozygous familial hypercholesterolemia: Phenotype rules! Commentary on the study of Raal et al.
    Atherosclerosis. 2016 Mar 14. pii: S0021-9150(16)30090.
    PubMed     Text format    


  183. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Text format     Abstract available


  184. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Text format     Abstract available


  185. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  186. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  187. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    February 2016
  188. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Text format     Abstract available


  189. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Text format     Abstract available


    January 2016
  190. LATET SC, Van Craenenbroeck AH, Van Herck PL, Van Craenenbroeck EM, et al
    A critical view of monocyte subpopulations in human hypercholesterolemia.
    Atherosclerosis. 2016 Jan 14. pii: S0021-9150(16)30021.
    PubMed     Text format    


  191. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Text format     Abstract available


  192. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  193. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


    December 2015
  194. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Text format     Abstract available


  195. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Text format     Abstract available


    October 2015
  196. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.
    PubMed     Text format    


  197. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Text format     Abstract available


    September 2015
  198. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Text format     Abstract available


  199. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.
    PubMed     Text format    


  200. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Text format     Abstract available


  201. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Text format     Abstract available


  202. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Text format     Abstract available


  203. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Text format     Abstract available


    August 2015
  204. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Text format     Abstract available


    July 2015
  205. BOS S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, et al
    Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Atherosclerosis. 2015;242:226-229.
    PubMed     Text format     Abstract available


  206. PEREIRA C, Miname MH, Makdisse MR, Watanabe C, et al
    Peripheral arterial disease in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;242:174-178.
    PubMed     Text format     Abstract available


  207. STOCK J, Hayes C
    Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.
    Atherosclerosis. 2015;242:277-280.
    PubMed     Text format    


  208. GALEMA-BOERS JM, Versmissen J, Roeters van Lennep HW, Dusault-Wijkstra JE, et al
    Cascade screening of familial hypercholesterolemia must go on.
    Atherosclerosis. 2015;242:415-417.
    PubMed     Text format     Abstract available


    June 2015
  209. KWON M, Han SM, Kim DI, Rhee MY, et al
    Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;242:8-12.
    PubMed     Text format     Abstract available


  210. BARRIOS C, Pascual J, Otero S, Soler MJ, et al
    Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Atherosclerosis. 2015;242:37-44.
    PubMed     Text format     Abstract available


  211. WANG X, Guan L, Zhao Y, Lei L, et al
    Plasma cholesterol-lowering activity of dietary dihydrocholesterol in hypercholesterolemia hamsters.
    Atherosclerosis. 2015;242:77-86.
    PubMed     Text format     Abstract available


  212. AHN HY, Kim M, Chae JS, Ahn YT, et al
    Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia.
    Atherosclerosis. 2015;241:649-656.
    PubMed     Text format     Abstract available


  213. MINICOCCI I, Prisco C, Montali A, Di Costanzo A, et al
    Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach.
    Atherosclerosis. 2015;242:618-624.
    PubMed     Text format     Abstract available


  214. ITO MK
    Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature.
    Atherosclerosis. 2015 Jun 11. pii: S0021-9150(15)01366.
    PubMed     Text format     Abstract available


  215. BESSELING J, Sjouke B, Kastelein JJ
    Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).
    Atherosclerosis. 2015;241:597-606.
    PubMed     Text format     Abstract available


  216. AUSCHER S, Heinsen L, Nieman K, Vinther KH, et al
    Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography.
    Atherosclerosis. 2015;241:579-587.
    PubMed     Text format     Abstract available


  217. BRAAMSKAMP MJ, Kusters DM, Wiegman A, Avis HJ, et al
    Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
    Atherosclerosis. 2015;241:427-432.
    PubMed     Text format     Abstract available


  218. THOMPSON GR
    Obituary of Dr N.B. Myant.
    Atherosclerosis. 2015;240:437-8.
    PubMed     Text format    


  219. GERARDS MC, Terlou RJ, Yu H, Koks CH, et al
    Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Atherosclerosis. 2015;240:415-23.
    PubMed     Text format     Abstract available


    May 2015
  220. RABACCHI C, Pisciotta L, Cefalu AB, Noto D, et al
    Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
    Atherosclerosis. 2015;241:79-86.
    PubMed     Text format     Abstract available


  221. POTI F, Ceglarek U, Burkhardt R, Simoni M, et al
    SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet.
    Atherosclerosis. 2015;240:212-5.
    PubMed     Text format     Abstract available


  222. MASANA L, Pedro-Botet J, Civeira F
    IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Atherosclerosis. 2015;240:161-2.
    PubMed     Text format    


  223. ZHANG T, Zhang C, Zhang Y, Tang F, et al
    Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Atherosclerosis. 2015;240:144-8.
    PubMed     Text format     Abstract available


  224. KOOPAL C, Retterstol K, Sjouke B, Hovingh GK, et al
    Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Atherosclerosis. 2015;240:90-7.
    PubMed     Text format     Abstract available


    April 2015
  225. DE BACKER G, Besseling J, Chapman J, Hovingh GK, et al
    Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
    Atherosclerosis. 2015;241:169-175.
    PubMed     Text format     Abstract available


    March 2015
  226. ALIS R, Sanchis-Gomar F, Risso-Ballester J, Perez-Quilis C, et al
    Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis.
    Atherosclerosis. 2015;239:38-42.
    PubMed     Text format     Abstract available


  227. ODA E
    Cross-sectional and longitudinal associations between serum bilirubin and dyslipidemia in a health screening population.
    Atherosclerosis. 2015;239:31-7.
    PubMed     Text format     Abstract available


    February 2015
  228. ETXEBARRIA A, Benito-Vicente A, Stef M, Ostolaza H, et al
    Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats.
    Atherosclerosis. 2015;238:304-12.
    PubMed     Text format     Abstract available


  229. SHIMIZU M, Furusyo N, Mitsumoto F, Takayama K, et al
    Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS).
    Atherosclerosis. 2015;238:207-12.
    PubMed     Text format     Abstract available


    September 2014
  230. FOLSE HJ, Goswami D, Rengarajan B, Budoff M, et al
    Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Atherosclerosis. 2014;236:154-61.
    PubMed     Text format     Abstract available


    July 2014
  231. PRENNER SB, Mulvey CK, Ferguson JF, Rickels MR, et al
    Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.
    Atherosclerosis. 2014;236:244-250.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: